Investor Presentaiton

Financial Metrics -EBIDTA stood at -27.1% for Q3 FY23 (before CSR & ESOP) METROPOLIS The Pathology Specialist Operating EBIDTA for labs started before April 2022 stood @ 28.3%, dilution of ~120 bps was on account of our Lab addition & Network expansion strategy. New Network has contributed ~3% of Revenues for Q3FY23 Total Revenue EBITDA (Before CSR & ESOP) +28% +22% 274.7 293.1 285.5 89.7 80.5 77.2 222.8 63.1 Q3FY20 Q3FY21 Q3FY22 Q3FY23 Q3FY20 Q3FY21 Q3FY22 Q3FY23 Reported EBITDA Profit after Tax (PAT) +16% -15% 86.7 58.6 76.2 72.7 62.7 42.0 Q3FY20 Q3FY21 Q3FY22 Q3FY23 41.2 35.9 Q3FY20 Q3FY21 Q3FY22 Q3FY23 EBIDTA margins were impacted due to our investments in building the network expansions of Lab & Centers. EBIDTA margins would have been higher ~120 bps on a like to like basis PAT has been impacted due to higher finance cost on account of Hi-Tech Acquisition & higher depreciation on account of Investments done to fuel the future growth engines With the largest test menu, Pan-India Specialized Diagnostic player; the trust created over the years in Pathology makes Company well placed to outgrow the Competition as market share shifts towards the organized sector for quality testing with precision in outcomes ✓ Despite our Investments done in technology & initiatives to increase our D2C business, margins stood strong near the pre-covid levels. We expect the same to continue for the coming quarters Q3FY22 includes Hitech Diagnostics w.e.f 22nd Oct 2021 9

View entire presentation